Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2017

  • ID: 4410156
  • Report
  • 284 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Admedus Ltd
  • Clemson University
  • Edwards Lifesciences Corp
  • JC Medical, Inc.
  • Mitralix Ltd.
  • St. Jude Medical LLC
  • MORE
Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2017" provides an overview of Transcatheter Heart Valves currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Heart Valves pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Transcatheter Heart Valves under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transcatheter Heart Valves and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transcatheter Heart Valves under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Admedus Ltd
  • Clemson University
  • Edwards Lifesciences Corp
  • JC Medical, Inc.
  • Mitralix Ltd.
  • St. Jude Medical LLC
  • MORE
1 Table of Contents

2 Introduction
2.1 Transcatheter Heart Valves Overview

3 Products under Development
3.1 Transcatheter Heart Valves - Pipeline Products by Stage of Development
3.2 Transcatheter Heart Valves - Pipeline Products by Segment
3.3 Transcatheter Heart Valves - Pipeline Products by Territory
3.4 Transcatheter Heart Valves - Pipeline Products by Regulatory Path
3.5 Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date
3.6 Transcatheter Heart Valves - Ongoing Clinical Trials

4 Transcatheter Heart Valves - Pipeline Products under Development by Companies
4.1 Transcatheter Heart Valves Companies - Pipeline Products by Stage of Development
4.2 Transcatheter Heart Valves - Pipeline Products by Stage of Development

5 Transcatheter Heart Valves Companies and Product Overview
5.1 4C Medical Technologies Inc Company Overview
5.1.1 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Admedus Ltd Company Overview
5.2.1 Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.3 Aegis Surgical Limited Company Overview
5.3.1 Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview
5.4 Annulon Company Overview
5.4.1 Annulon Pipeline Products & Ongoing Clinical Trials Overview
5.5 AorTech International Plc Company Overview
5.5.1 AorTech International Plc Pipeline Products & Ongoing Clinical Trials Overview
5.6 Arbor Surgical Technologies, Inc. Company Overview
5.6.1 Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.7 Boston Scientific Corp Company Overview
5.7.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.8 Celyad SA Company Overview
5.8.1 Celyad SA Pipeline Products & Ongoing Clinical Trials Overview
5.9 Cephea Valve Technologies, Inc. Company Overview
5.9.1 Cephea Valve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.10 Children's Hospital Boston Company Overview
5.10.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
5.11 Clemson University Company Overview
5.11.1 Clemson University Pipeline Products & Ongoing Clinical Trials Overview
5.12 Colibri Heart Valve, LLC Company Overview
5.12.1 Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.13 Daidalos Solutions BV Company Overview
5.13.1 Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview
5.14 Direct Flow Medical Inc Company Overview
5.14.1 Direct Flow Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.15 DSM Dyneema B.V. Company Overview
5.15.1 DSM Dyneema B.V. Pipeline Products & Ongoing Clinical Trials Overview
5.16 Dura LLC Company Overview
5.16.1 Dura LLC Pipeline Products & Ongoing Clinical Trials Overview
5.17 Edwards Lifesciences Corp Company Overview
5.17.1 Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview
5.18 Emory University Company Overview
5.18.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview
5.19 Endoluminal Technology Research, LLC Company Overview
5.19.1 Endoluminal Technology Research, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.20 Florida International University Company Overview
5.20.1 Florida International University Pipeline Products & Ongoing Clinical Trials Overview
5.21 Hansen Medical Inc Company Overview
5.21.1 Hansen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 HighLife SAS Company Overview
5.22.1 HighLife SAS Pipeline Products & Ongoing Clinical Trials Overview
5.23 HLT, Inc. Company Overview
5.23.1 HLT, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.24 InterVene Inc. Company Overview
5.24.1 InterVene Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.25 JC Medical, Inc. Company Overview
5.25.1 JC Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.26 JenaValve Technology GmbH Company Overview
5.26.1 JenaValve Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.27 LivaNova PLC Company Overview
5.27.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview
5.28 Mayo Clinic US Company Overview
5.28.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview
5.29 Medtronic plc Company Overview
5.29.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
5.30 Meril Life Sciences Pvt Ltd Company Overview
5.30.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.31 Micro Interventional Devices, Inc. Company Overview
5.31.1 Micro Interventional Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.32 MicroPort Scientific Corp Company Overview
5.32.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.33 Mitralix Ltd. Company Overview
5.33.1 Mitralix Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.34 MitrAssist Ltd. Company Overview
5.34.1 MitrAssist Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.35 MValve Technologies Ltd. Company Overview
5.35.1 MValve Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.36 NaviGate Cardiac Structures, Inc. Company Overview
5.36.1 NaviGate Cardiac Structures, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.37 Neovasc Inc Company Overview
5.37.1 Neovasc Inc Pipeline Products & Ongoing Clinical Trials Overview
5.38 PolyNova Cardiovascular LLC Company Overview
5.38.1 PolyNova Cardiovascular LLC Pipeline Products & Ongoing Clinical Trials Overview
5.39 RegenaGraft Company Overview
5.39.1 RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview
5.40 SAS Cormove Company Overview
5.40.1 SAS Cormove Pipeline Products & Ongoing Clinical Trials Overview
5.41 Sino Medical Sciences Technology Inc Company Overview
5.41.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
5.42 St. Jude Medical LLC Company Overview
5.42.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
5.43 Symetis AG Company Overview
5.43.1 Symetis AG Pipeline Products & Ongoing Clinical Trials Overview
5.44 Thubrikar Aortic Valve, Inc. Company Overview
5.44.1 Thubrikar Aortic Valve, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.45 Trinity College Dublin Company Overview
5.45.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview
5.46 University College London Company Overview
5.46.1 University College London Pipeline Products & Ongoing Clinical Trials Overview
5.47 University of California San Francisco Company Overview
5.47.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
5.48 University of Cambridge Company Overview
5.48.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview
5.49 University of Iowa Company Overview
5.49.1 University of Iowa Pipeline Products & Ongoing Clinical Trials Overview
5.50 Valtech Cardio Ltd Company Overview
5.50.1 Valtech Cardio Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.51 Vascular Concepts Ltd Company Overview
5.51.1 Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.52 Venus MedTech Company Overview
5.52.1 Venus MedTech Pipeline Products & Ongoing Clinical Trials Overview
5.53 Xeltis AG Company Overview
5.53.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview

6 Transcatheter Heart Valves- Recent Developments
6.1 Sep 21, 2017: Medtronic Announces Clinical Study to Evaluate the CoreValve Evolut PRO System in 'Everyday' Clinical Practice
6.2 Sep 12, 2017: Neovasc Provides Tiara Clinical Update
6.3 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY
6.4 Sep 01, 2017: Decision from Appeals Court upholds lower court decisions but denies injunction
6.5 Aug 30, 2017: NaviGate Cardiac Structures reports world's first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient
6.6 Aug 22, 2017: Medtronic Reports First Quarter Financial Results
6.7 Aug 16, 2017: AorTech International: Audited results for the year ended 31 March 2017
6.8 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261%
6.9 Aug 10, 2017: Neovasc Announces Results for the Second Quarter of 2017
6.10 Aug 03, 2017: 4C Medical's Novel Mitral Regurgitation Therapy Highlighted at CVI 2017 Innovation Summit
6.11 Jul 31, 2017: Medtronic Announces CE Mark and European Launch of CoreValve Evolut PRO Transcatheter Valve with Advanced Sealing
6.12 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017
6.13 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017
6.14 Jul 10, 2017: Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
6.15 Jul 07, 2017: MPSC New COO Glendy Wang on Board
6.16 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.17 Jun 16, 2017: Neovasc Announces German Court Ruling
6.18 Jun 15, 2017: Neovasc Tiara Featured in TVT 2017 Presentation
6.19 Jun 15, 2017: 4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum
6.20 Jun 06, 2017: First U.S. Patients Enrolled in an Early Feasibility Study of HLT's New Transcatheter Aortic Valve Replacement System
6.21 Jun 05, 2017: FDA expands use of Sapien 3 artificial heart valve for high-risk patients
6.22 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
6.23 May 19, 2017: Celyad Announces First Quarter 2017 Business Update
6.24 May 17, 2017: Edwards' Novel Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes
6.25 May 16, 2017: Real-World Evidence With Edwards SAPIEN 3 Transcatheter Valve Confirms Beneficial Patient Outcomes From Clinical Trials
6.26 May 16, 2017: The Boston Scientific LOTUS Valve System Demonstrated Superior Efficacy to CoreValve in Global REPRISE III Trial at One Year
6.27 May 16, 2017: New Data on CoreValve and Evolut R Self-Expanding TAVI Systems Show Excellent Clinical Outcomes in Routine Clinical Practice
6.28 May 11, 2017: Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
6.29 May 10, 2017: Boston Scientific to Present The LOTUS Valve System at EuroPCR 2017
6.30 May 10, 2017: Neovasc Announces Results for the First Quarter of 2017
6.31 Apr 28, 2017: Venus Medtech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China English
6.32 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017
6.33 Apr 26, 2017: NaviGate Cardiac Structures Reports First Heterotopic Transcatheter GATE Tricuspid Valved Stent Successful Implantation
6.34 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results
6.35 Apr 05, 2017: Aurora Health Care Heart Experts Among First in Nation to Implant New Heart Valve to Treat Aortic Stenosis
6.36 Apr 04, 2017: HLT Announces First Patient Enrollments in a Feasibility Study of a New Transcatheter Aortic Valve Replacement System
6.37 Mar 30, 2017: MPSC Announces 2016 Annual Results
6.38 Mar 23, 2017: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2016
6.39 Mar 22, 2017: Medtronic Receives FDA Approval for CoreValve Evolut Pro Transcatheter Valve with Advanced Sealing
6.40 Mar 17, 2017: Landmark SURTAVI Clinical Trial Shows Transcatheter Aortic Valve Replacement with the Self-Expanding Platform Performs as Well as Surgery in Intermediate Risk Severe Aortic Stenosis Patients
6.41 Mar 10, 2017: Neovasc Announces TSX Symbol Change to NVCN
6.42 Mar 09, 2017: Boston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation
6.43 Mar 03, 2017: Colibri Heart Valve Receives ISO 13485 and EN ISO 13485 Certification
6.44 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
6.45 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
6.46 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
6.47 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results
6.48 Jan 19, 2017: LHSC First in Ontario to Implant Canadian made Mitral Valve Device
6.49 Jan 18, 2017: Neovasc Announces Update in Litigation with CardiAQ
6.50 Jan 17, 2017: Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies
6.51 Dec 30, 2016: NaviGate Cardiac Structures Reports World’s First Transcatheter Tricuspid Valved Stent is Successfully Implanted
6.52 Dec 26, 2016: MicroPort Completes Patient Enrollment of VitaFlow Pre-market Clinical Trial
6.53 Dec 23, 2016: Neovasc Announces Update in Litigation with CardiAQ
6.54 Dec 21, 2016: AorTech International: Unaudited Interim Results For the six months ended 30 September 2016
6.55 Dec 21, 2016: AorTech Shares Dive As Losses And Lawsuit Against Former CEO Continue
6.56 Dec 08, 2016: Aurora Heart and Vascular team hits milestone of 1,000th valve replacement procedure at Aurora St. Luke’s
6.57 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
6.58 Dec 06, 2016: Neovasc Provides Update On Its Tiara Mitral Valve Clinical Program
6.59 Dec 01, 2016: Medtronic Announces Reimbursement Approval and Launch of CoreValve Evolut R System in Japan
6.60 Nov 28, 2016: Neovasc Receives Regulatory Approval To Initiate TIARA II CE Mark Study
6.61 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
6.62 Nov 18, 2016: Celyad Announces Third Quarter 2016 Business Update
6.63 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
6.64 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction
6.65 Nov 14, 2016: Neovasc Reports Third Quarter Results for 2016
6.66 Nov 03, 2016: Study Deems Transcaval Valve Replacement Pioneered at Henry Ford Hospital ‘Successful’
6.67 Nov 01, 2016: Medtronic Harmony Transcatheter Pulmonary Valve Demonstrates Positive Early Clinical Outcomes At One Year
6.68 Nov 01, 2016: Edwards Sapien Valves Demonstrate Excellent Durability In 5-Year Echo Study
6.69 Nov 01, 2016: Neovasc Announces Update in Litigation with CardiAQ
6.70 Nov 01, 2016: Patients with Severe Aortic Stenosis and Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve replacement
6.71 Nov 01, 2016: Xeltis Announces Multidisciplinary Scientific Advisory Board of Global Leading Experts
6.72 Nov 01, 2016: Early And Sustained Quality Of Life Improvements Seen For Intermediate Risk Patients Treated With Edwards Transcatheter Valves
6.73 Oct 31, 2016: New Data on Medtronic Evolut R TAVR System Show Excellent 'Real-World' Outcomes in Global Patient Population
6.74 Oct 31, 2016: New method for performing aortic valve replacement proves successful in high risk patients
6.75 Oct 27, 2016: The Successful Worldwide First in Human Implantation of an Innovative Aortic Valve from Colibri Heart Valve and Venus Medtech with Disruptive Dry Tissue Technology Conducted
6.76 Oct 26, 2016: Neovasc to Present Tiara Data at TCT in Washington DC
6.77 Oct 26, 2016: Medtronic Announces FDA Approval of New Recaptureable TAVR System Available for Severe Aortic Stenosis Patients with Large Anatomies
6.78 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
6.79 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results
6.80 Oct 24, 2016: Boston Scientific announced key Presentations on Lotus Valve System at Transcatheter Cardiovascular Therapeutics 2016
6.81 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results
6.82 Oct 14, 2016: AorTech International Announces Board Changes
6.83 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer

7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Transcatheter Heart Valves - Pipeline Products by Stage of Development
Table 2: Transcatheter Heart Valves - Pipeline Products by Segment
Table 3: Transcatheter Heart Valves - Pipeline Products by Territory
Table 4: Transcatheter Heart Valves - Pipeline Products by Regulatory Path
Table 5: Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date
Table 6: Transcatheter Heart Valves - Ongoing Clinical Trials
Table 7: Transcatheter Heart Valves Companies - Pipeline Products by Stage of Development
Table 8: Transcatheter Heart Valves - Pipeline Products by Stage of Development
Table 9: 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: TMVR Implant - Product Status
Table 11: TMVR Implant - Product Description
Table 12: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Transcatheter Aortic Valve Replacement - Product Status
Table 14: Transcatheter Aortic Valve Replacement - Product Description
Table 15: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 16: pTAo-TAVR - Product Status
Table 17: pTAo-TAVR - Product Description
Table 18: Annulon Pipeline Products & Ongoing Clinical Trials Overview
Table 19: Mitral Valve Replacement Device - Product Status
Table 20: Mitral Valve Replacement Device - Product Description
Table 21: AorTech International Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 22: AorTech Polymer Valve - Product Status
Table 23: AorTech Polymer Valve - Product Description
Table 24: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Trilogy Aortic Valve System - Product Status
Table 26: Trilogy Aortic Valve System - Product Description
Table 27: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 28: ACURATE TAVR - Product Status
Table 29: ACURATE TAVR - Product Description
Table 30: Gen 4 Lotus Valve System - Product Status
Table 31: Gen 4 Lotus Valve System - Product Description
Table 32: Lotus Edge Sheath 15F - Product Status
Table 33: Lotus Edge Sheath 15F - Product Description
Table 34: Lotus Edge Valve System - 21 mm - Product Status
Table 35: Lotus Edge Valve System - 21 mm - Product Description
Table 36: Lotus Edge Valve System - 23 mm - Product Status
Table 37: Lotus Edge Valve System - 23 mm - Product Description
Table 38: Lotus Edge Valve System - 25 mm - Product Status
Table 39: Lotus Edge Valve System - 25 mm - Product Description
Table 40: Lotus Edge Valve System - 27 mm - Product Status
Table 41: Lotus Edge Valve System - 27 mm - Product Description
Table 42: Lotus Edge Valve System - 29 mm - Product Status
Table 43: Lotus Edge Valve System - 29 mm - Product Description
Table 44: Lotus Valve System - 21 mm - Product Status
Table 45: Lotus Valve System - 21 mm - Product Description
Table 46: Lotus Valve System - 23 mm - Product Status
Table 47: Lotus Valve System - 23 mm - Product Description
Table 48: Lotus Valve System - 25 mm - Product Status
Table 49: Lotus Valve System - 25 mm - Product Description
Table 50: Lotus Valve System - 27 mm - Product Status
Table 51: Lotus Valve System - 27 mm - Product Description
Table 52: Lotus Valve System - 29 mm - Product Status
Table 53: Lotus Valve System - 29 mm - Product Description
Table 54: Transaortic Sheath - Product Status
Table 55: Transaortic Sheath - Product Description
Table 56: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 57: Lotus Valve System - 23 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 58: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers
Table 59: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 60: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 61: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 62: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 63: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX
Table 64: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 65: Lotus Valve System - 27 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 66: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 67: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 68: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 69: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 70: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX
Table 71: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 72: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 73: Lotus Valve System - 25 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 74: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 75: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 76: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 77: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 78: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 79: Lotus Valve System - 21 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 80: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 81: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 82: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 83: Lotus Valve System - 29 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
Table 84: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 85: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 86: Lotus Valve System - 29 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 87: Lotus Edge Valve System - 23 mm - Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation
Table 88: Lotus Edge Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 89: Lotus Edge Valve System - 23 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Table 90: Lotus Edge Valve System - 29 mm - Reprise Edge 29 Mm Eu Study: Repositionable Percutaneous Replacement of Native Stenotic Aortic Valve Through Implantation of Lotus Edge 29 Mm Valve - Evaluation of Safety and Performance
Table 91: Lotus Edge Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 92: Lotus Edge Valve System - 25 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Table 93: Lotus Edge Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS)
Table 94: Lotus Edge Valve System - 27 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Table 95: Celyad SA Pipeline Products & Ongoing Clinical Trials Overview
Table 96: Mitral Valve Neo-chordae - Product Status
Table 97: Mitral Valve Neo-chordae - Product Description
Table 98: Cephea Valve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 99: Mitral Valve Replacement Device - Product Status
Table 100: Mitral Valve Replacement Device - Product Description
Table 101: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
Table 102: Two Piece Replacement Heart Valve - Product Status
Table 103: Two Piece Replacement Heart Valve - Product Description
Table 104: Clemson University Pipeline Products & Ongoing Clinical Trials Overview
Table 105: Transcatheter Bioprosthetic Heart Valve - Product Status
Table 106: Transcatheter Bioprosthetic Heart Valve - Product Description
Table 107: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 108: Colibri Aortic Heart Valve - 24mm - Product Status
Table 109: Colibri Aortic Heart Valve - 24mm - Product Description
Table 110: Colibri Aortic Heart Valve - 21mm - Product Status
Table 111: Colibri Aortic Heart Valve - 21mm - Product Description
Table 112: Colibri Aortic Heart Valve - 27mm - Product Status
Table 113: Colibri Aortic Heart Valve - 27mm - Product Description
Table 114: Colibri TAVI System - Product Status
Table 115: Colibri TAVI System - Product Description
Table 116: Delta Aortic Heart Valve - Product Status
Table 117: Delta Aortic Heart Valve - Product Description
Table 118: Venibri Transcatheter Heart Valve System - Product Status
Table 119: Venibri Transcatheter Heart Valve System - Product Description
Table 120: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview
Table 121: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Status
Table 122: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Description
Table 123: Sutureless Trans-Catheter Mitral Valve Replacement (TMVR) - Product Status

List of Figures
Figure 1: Transcatheter Heart Valves - Pipeline Products by Stage of Development
Figure 2: Transcatheter Heart Valves - Pipeline Products by Segment
Figure 3: Transcatheter Heart Valves - Pipeline Products by Territory
Figure 4: Transcatheter Heart Valves - Pipeline Products by Regulatory Path
Figure 5: Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date
Figure 6: Transcatheter Heart Valves - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4C Medical Technologies Inc
  • Admedus Ltd
  • Aegis Surgical Limited
  • Annulon
  • AorTech International Plc
  • Arbor Surgical Technologies, Inc.
  • Boston Scientific Corp
  • Celyad SA
  • Cephea Valve Technologies, Inc.
  • Children's Hospital Boston
  • Clemson University
  • Colibri Heart Valve, LLC
  • Daidalos Solutions BV
  • Direct Flow Medical Inc
  • DSM Dyneema B.V.
  • Dura LLC
  • Edwards Lifesciences Corp
  • Emory University
  • Endoluminal Technology Research, LLC
  • Florida International University
  • Hansen Medical Inc
  • HighLife SAS
  • HLT, Inc.
  • InterVene Inc.
  • JC Medical, Inc.
  • JenaValve Technology GmbH
  • LivaNova PLC
  • Mayo Clinic US
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • Micro Interventional Devices, Inc.
  • MicroPort Scientific Corp
  • Mitralix Ltd.
  • MitrAssist Ltd.
  • MValve Technologies Ltd.
  • NaviGate Cardiac Structures, Inc.
  • Neovasc Inc
  • PolyNova Cardiovascular LLC
  • RegenaGraft
  • SAS Cormove
  • Sino Medical Sciences Technology Inc
  • St. Jude Medical LLC
  • Symetis AG
  • Thubrikar Aortic Valve, Inc.
  • Trinity College Dublin
  • University College London
  • University of California San Francisco
  • University of Cambridge
  • University of Iowa
  • Valtech Cardio Ltd
  • Vascular Concepts Ltd
  • Venus MedTech
  • Xeltis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll